Studying the Time of
Humankind

Medytox is a company studying the time of humankind.

The Global Leader of Botulinum Toxin Industry

Medytox is a global leader in botulinum toxin industry.

Neuramis Time

Neuramis® is a hyaluronic acid filler product made by Medytox.

Biotechnology that
changes the future

All of Medytox starts from R&D.

Newsroom

read more

Medytox Vision 2022

Medytox has begun to step up its efforts to achieve Vision 2022.

Sales
$1 billion
Global Biopharmaceutical Company
TOP 20

Based on integrity and open communication, Medytox is building excellent capacity and system to meet the global standard with commitment and courage.
Furthermore, we are endeavoring to reach $1 billion in sales, $10 billion in market value,
and to become one of the world's top 20 biopharmaceutical companies by 2022.

Medytox AD/PR Video

Medytox, a pharmaceutical company expanding beyond domestic boundaries to win global recognition.
Meet us from our first step in 2000 to now and the future.

Medytox Offices & Facilities

While meeting global quality standards, Medytox has become one of the leading global companies.

Medytox Global Business Center
Medytox global business center
Medytox R&D Center (Gwanggyo)
One-Stop R&D system facility for developing new bio-drugs
Medytox Plant I (Ochang)
Korea’s first botulinum toxin production facility
and filler production facility
Medytox Plant II (Osong)
US FDA’s cGMP and Europe EMA’s EU GMP
compliant botulinum toxin production facility
Medytox Plant III (Osong)
The world’s largest botulinum toxin and filler product
production facility that implemented

* Single-use System: Using single-use sterile bags
to shorten the process

Medytox at a Glance

over 60 countries
Korea's No.1 Botulinum Toxin Market Share
Vision $1billion in Sales in 2022
More than 26 r&d Pipeline

Medytox Global Network

Starting with a Taiwan joint venture "Medytox Taiwan", Medytox established a China joint venture "Medybloom China", a Hong Kong joint venture "Medytox Hong Kong", a Thailand joint venture "MedyCeles", and a 100% owned local subsidiary "MDT International Inc." in Japan.